283 related articles for article (PubMed ID: 31709477)
1. The impact of different criteria sets on early remission and identifying its predictors in rheumatoid arthritis: results from an observational cohort (2009-2018).
Xie W; Li J; Zhang Z
Clin Rheumatol; 2020 Feb; 39(2):381-389. PubMed ID: 31709477
[TBL] [Abstract][Full Text] [Related]
2. Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018.
Xie W; Li J; Zhang X; Sun X; Zhang Z
Int J Rheum Dis; 2019 Sep; 22(9):1670-1678. PubMed ID: 31297977
[TBL] [Abstract][Full Text] [Related]
3. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
[TBL] [Abstract][Full Text] [Related]
4. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
[TBL] [Abstract][Full Text] [Related]
5. Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis.
Liu JJ; Li R; Gan YZ; Zhang RJ; Li J; Cai YM; Zhao JX; Liao H; Xu J; Shi LJ; Li J; Li SG; Sun XL; He J; Liu X; Ye H; Li ZG
Chin Med J (Engl); 2019 May; 132(9):1009-1014. PubMed ID: 30946065
[TBL] [Abstract][Full Text] [Related]
6. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
7. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML; Haavardsholm EA; Rudin A; Nordström D; Nurmohamed M; Gudbjornsson B; Lampa J; Hørslev-Petersen K; Uhlig T; Grondal G; Østergaard M; Heiberg MS; Twisk J; Lend K; Krabbe S; Hyldstrup LH; Lindqvist J; Hultgård Ekwall AK; Grøn KL; Kapetanovic M; Faustini F; Tuompo R; Lorenzen T; Cagnotto G; Baecklund E; Hendricks O; Vedder D; Sokka-Isler T; Husmark T; Ljoså MA; Brodin E; Ellingsen T; Söderbergh A; Rizk M; Olsson ÅR; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Laurberg TB; Bakland G; Olsen IC; van Vollenhoven R;
BMJ; 2020 Dec; 371():m4328. PubMed ID: 33268527
[TBL] [Abstract][Full Text] [Related]
8. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
9. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
10. Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis.
Ramírez J; Inciarte-Mundo J; Cuervo A; Celis R; Ruiz-Esquide V; Castellanos-Moreira R; Ponce A; Gómez-Puerta JA; Sanmartí R; Cañete JD
Clin Rheumatol; 2021 Jul; 40(7):2665-2672. PubMed ID: 33506371
[TBL] [Abstract][Full Text] [Related]
11. Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study.
Zhu H; Li R; Da Z; Bi L; Li X; Li Y; Liu C; Zhang F; Li Z; Liu X; Zhang Z; Sun L; Wang Y; Zhang W; Jiang Q; Chen J; Chen Q; Li Z; Wu L; Qi W; Xu J; Cui X; Wang X; Li L; Leng X; Wang G; Zhao D; Jiang L; He D; Liu X; Li L; Fang Y; Huang C; Wu H; Hu S; Li Q; Song H; Xiao W; Gong L; Zhang L; Li X; Li Z; Su Y
Clin Rheumatol; 2018 Mar; 37(3):597-605. PubMed ID: 29116543
[TBL] [Abstract][Full Text] [Related]
12. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
Mack ME; Hsia E; Aletaha D
Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
[TBL] [Abstract][Full Text] [Related]
13. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
[TBL] [Abstract][Full Text] [Related]
14. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
15. Assessing remission in clinical practice.
Mierau M; Schoels M; Gonda G; Fuchs J; Aletaha D; Smolen JS
Rheumatology (Oxford); 2007 Jun; 46(6):975-9. PubMed ID: 17341506
[TBL] [Abstract][Full Text] [Related]
16. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
Kaneko Y; Kondo H; Takeuchi T
J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
18. Predictors and the optimal duration of sustained remission in rheumatoid arthritis.
Yilmaz-Oner S; Gazel U; Can M; Atagunduz P; Direskeneli H; Inanc N
Clin Rheumatol; 2019 Nov; 38(11):3033-3039. PubMed ID: 31270696
[TBL] [Abstract][Full Text] [Related]
19. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
[TBL] [Abstract][Full Text] [Related]
20. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
